Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993325 | 0.90 | ADRB3 (0.67) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL2991106 | 0.85 | ADRB3 (0.62) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL3000457 | 0.84 | ADRB1 (0.71) | ADRB3ADRB2ADRB1DNM1MAPT | |
| SCHEMBL2994463 | 0.83 | ADRB3 (0.64) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL2991230 | 0.83 | ADRB3 (0.58) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL4607632 | 0.82 | MET (0.41) | ADRB3ADRB2ADRB1DNM1ALDH1A1 | |
| SCHEMBL2990928 | 0.82 | ADRB3 (0.71) | ADRB3ADRB2ADRB1DNM1ALDH1A1 | |
| SCHEMBL2997640 | 0.81 | ADRB3 (0.61) | ADRB3ADRB2ADRB1DNM1 | |
| SCHEMBL2988158 | 0.80 | ADRB2 (0.61) | ADRB3ADRB2ADRB1 | |
| SCHEMBL2992698 | 0.80 | ADRB3 (0.67) | ADRB3ADRB2ADRB1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | claimed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | claimed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-7786142-B2 | Heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| EP-1945612-A2 | HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS | Orchid Research Laboratories Limited (IN) | 2008-07-23 | — | — | EP | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2007-05-17 | — | — | US | disclosed |
| WO-2007042912-A2 | HETEROCYCLIC COMPOUNDS AS PSTAT3/IL-6 INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111998-A1 | Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors | IL6, IL6ST, STAT3 | ADRB3 3238/4885ADRB2 4160/4885ADRB1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.